ArticleStress biology2025
Nontoxic mesoporous silica nanoparticles protect Physcomitrium patens against salt stress.
Article in Stress biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mosses play a crucial role in environmental protection, ecological preservation, and horticulture. While the effects of nanomaterials on angiosperms have been widely studied, their impact on bryophytes remains underexplored. In this study, we investigated the effects of mesoporous silica nanoparticles (MSNs) and virus-like mesoporous silica nanoparticles (VMSNs) on the model moss species Physcomitrium patens (P. patens). Our results revealed that MSNs, with an average size of approximately 123 nm, are nontoxic to P. patens and enhance its salt tolerance. The expression of key genes involved in stress responses were significantly induced in MSN-treated plants under salt stress, including peroxidase (POX), L-ascorbate oxidase (L-AO), alternative oxidase (AOX), and calcium-dependent protein kinase (CPK). MSN treatment reduced the accumulation of H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.